Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

UK's Bingham expects Omicron vaccine impact to be known in a week

Stock MarketsDec 01, 2021 17:27
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A nurse prepares a vaccination at the Hartlepool Town Hall Theatre vaccination centre, as the spread of the coronavirus disease (COVID-19) continues in Hartlepool, Britain, December 1 2021. REUTERS/Lee Smith/File Photo

LONDON (Reuters) - Kate Bingham, the former head of the UK's COVID-19 Vaccine Taskforce who secured millions of doses for the country, said scientists should know within a week whether existing shots are effective against the Omicron variant of the coronavirus.

Bingham, a venture capitalist who backed multiple vaccines at the start of the pandemic to secure early access for Britain, said she currently expected that the leading shots would still show efficacy.

"The question is do they have the same level of efficacy?" she said in an interview at the Reuters Next conference on Wednesday.

Bingham, who has returned to her role as managing partner at SV Health Investors, said Britain had built up the capability to quickly test existing vaccines against new variants.

"It's not something you can do overnight, but we will get data, I would have thought within a week as to whether or not the vaccines work or don't," she said.

Under Bingham's leadership, the UK taskforce ordered vaccines as they were still being trialled, securing supplies from Pfizer (NYSE:PFE), AstraZeneca (NASDAQ:AZN), Moderna (NASDAQ:MRNA) and others to give Britain a head start in the rollout.

She said on Wednesday that she had backed the vaccine from French company Valneva, which differs from others by relying on an inactivated virus similar to flu vaccines, because having a varied portfolio would be useful when variants emerged.

Britain has since cancelled the order.

"The idea of having that as a potential vaccine in our portfolio, knowing it was going to come on stream later than the earlier ones, was precisely that you could deal with variants," she said.

She added that "unfortunately" the Valneva contract had been cancelled. "I wasn't part of the decision so I don't know the basis of it," she said. "But I would have thought that was a useful vaccine to have in our panoply of tools to actually address variants and future pandemic strains."

To watch the Reuters Next conference please register here https://reutersevents.com/events/next/

UK's Bingham expects Omicron vaccine impact to be known in a week
 

Related Articles

Caterpillar Earnings, Revenue beat in Q4
Caterpillar Earnings, Revenue beat in Q4 By Investing.com - Jan 28, 2022

Investing.com - Caterpillar (NYSE:CAT) reported on Friday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations. Caterpillar announced...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Puk Pups
Puk Pups Dec 01, 2021 23:20
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Reuters about Omicron 101 times a day
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email